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Introduction 
 
The choice of primary endpoint for a clinical trial is one of the most 
important determinants of the ability of a clinical trial to demonstrate the efficacy 
of therapeutic agents. Physiological outcomes such as clinical laboratory 
values and doctor's assessment are often used with high reliability in clinical 
trials, since objectivity and doctor's judgment are regarded as important for drug 
development. However, among diseases, there are functional diseases in 
which no abnormality is observed in clinical laboratory values or diagnostic 
imaging. In these diseases, the development of evidence-based drugs is 
delayed due to lack of appropriate primary endpoints in clinical trials. Irritable 
bowel syndrome (IBS) is one such disease; patients are reported to be less 
satisfied with existing treatments and to repeatedly shop for doctors [1]. Finding 
variables that can properly evaluate drug efficacy and developing new drugs 
will increase the options for new treatments for patients who are struggling with 
IBS treatment and can fulfill the needs of the medical industry. The purpose of 
this study was to evaluate and examine clinically meaningful variables in clinical 
studies of ramosetron hydrochloride (ramosetron) for patients with IBS with 
diarrhea (IBS-D). 
 
Pathophysiology of IBS 
IBS is a functional disease characterized by prolonged persistence or 
recurrence of abnormal bowel habits and abdominal pain and discomfort 
without organic diseases or biochemical abnormalities [2]. IBS is not a life-
threatening disease, but has been shown to limit the activity of patients and to 
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negatively impact social functioning, with substantial economic loss [3]. It is also 
reported that IBS can severely compromise the patient’s quality of life (QOL), 
even to a greater extent than in patients with end-stage renal disease or 
patients with diabetes [4]. Surveys conducted outside Japan have reported that 
the estimated prevalence of IBS in the general population is from 5% to 20%, 
with about 200 new patients per 100,000 population per year [5, 6]. In Japan, a 
large population-based internet survey by Kanazawa et al. revealed that about 
16.5% of the survey population met the Rome III criteria for IBS, which is 
established by Rome committee, the international working group on Functional 
Bowel Disorders and Functional Abdominal Pain [7]. A web-based survey by 
Miwa that used Rome III showed that 13% of the respondents had IBS [8]. 
IBS as defined by the Rome III criteria [9] is classified into four 
subtypes: IBS-D, IBS with constipation (IBS-C), mixed-type IBS, and 
unsubtyped IBS. A variety of factors are considered to be involved in the 
etiology of IBS, including abnormal gastrointestinal motility, visceral 
hypersensitivity, abnormal brain–gut interactions, gastrointestinal infection and 
sociopsychological strain [10]. Stress-related disturbance of brain–gut 
interactions is a particularly important factor in functional gastrointestinal 
disorders including IBS [11]. IBS patients reported significantly more stress 
than controls without bowel dysfunction and the slope of the regression 
equation relating bowel symptoms to stress was significantly steeper for the 
IBS group [12]. 
Psychosocial stress causes stimulation of the hypothalamus, releasing 
corticotropin-releasing hormone (CRH), and causes abnormalities in 
gastrointestinal motility and lowering of the sensory threshold in the 
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gastrointestinal tract via neurotransmitters, such as 5-hydroxytryptamine, 
serotonin (5-HT) released from enteric nerves or enterochromaffin cells. Some 
evidence suggests that 5-HT has a crucial role in IBS-D pathophysiology. 
Patients with IBS-D show exaggerated colonic motility in response to colonic 
distention [13] and secretion of 5-HT [14]. Moreover, in animal studies and 
clinical pharmacological tests, 5-hydroxytryptamine 3 (5-HT3) receptor 
antagonists have been reported to suppress abnormalities of gastrointestinal 
motility (abnormal bowel movements) and a decrease in the sensory threshold 
in the gastrointestinal tract caused by CRH and stresses [15-17], which 
suggests involvement of the 5-HT3 receptor in the occurrence of IBS-D 
symptoms. 
 
Development of ramosetron 
Ramosetron, a potent and selective 5-HT3 receptor antagonist was 
developed at Astellas pharmaceutical company in Japan [15, 18-20] (Figure 1). 
In rats, ramosetron clearly reduces stress-induced diarrhea and defecation 
caused by CRH [15, 19]. In addition, ramosetron increases the threshold of 
abdominal pain responses induced by colonic distension in rats [21]. Thus, 
ramosetron is expected to improve IBS symptoms via reducing the vicious cycle 
for stress-related disturbance of brain–gut interactions. Figure 2 summarized 
pathophysiology of IBS and mode of action of ramosetron [21].  
The efficacy of ramosetron for patients with IBS-D was demonstrated 
based on the results of improvement of overall IBS symptoms in a previous 
phase II and III study [22, 23]. However, stratified analysis by sex using the chi-
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square test (two-sided significance level of 0.05) in the phase III study revealed 
that ramosetron did not show significant improvement compared to placebo in 
the global assessments of relief of the overall IBS symptoms of female patients 
[23]. Based on the above results, marketing approval was granted for the 
indication of “IBS-D in male patients” in Japan in July 2008. Subsequently, 
additional clinical studies were conducted to evaluate the efficacy and safety of 
ramosetron for female patients with IBS-D [24-26]. These studies indicated that 
2.5 µg/day of ramosetron was an effective treatment for female patients with 
IBS-D, in contrast to the optimal dose of ramosetron at 5 µg/day for male 
patients. Ramosetron was approved for use by women in May 2015. 
 
Efficacy variables in clinical trials 
Rome committee discussed primary variables in clinical studies for 
functional gastrointestinal tract disturbances including IBS. It was concluded 
that, since IBS is a syndrome, instead of evaluating individual symptoms the 
improvement of overall symptoms of the syndrome should be assessed and 
subjects should evaluate the effects of therapeutics because improvement of 
subjective symptoms is clinically important for IBS [27]. Consequently, IBS 
clinical trials commonly used patient-reported rating of change in overall IBS 
symptoms as the primary endpoint, which have included “Adequate relief” or 
“Satisfactory relief” and “Subject global assessment of relief” of IBS symptoms. 
Those endpoints required patients to average either specific symptoms or all 
signs and symptoms of IBS in a 1-week and then compare the weekly average 
to past period like before trial entry. Table 1 summarized primary variables used 
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in the clinical trials for the same class drug as ramosetron.  
As well, “global assessment of relief of overall IBS symptoms” was 
chosen to be the primary variables for previous clinical trials of ramosetron [22, 
23], and its efficacy was demonstrated. Abdominal pain and discomfort, which 
were the main subjective symptoms of patients with IBS-D, would be assessed 
by subjects as “global assessment of relief of abdominal pain/discomfort” and 
that symptoms of diarrhea, such as abnormal stool form, frequent bowel 
movement and defecation urgency, would be evaluated by patients as “global 
assessment of improvement in abnormal bowel habits”. These two global 
assessments focused on the main subjective symptoms in the patients with 
IBS-D and individual IBS symptoms were assessed as secondary valuables. 
Table 2 showed global assessments used in clinical trials of ramosetron. Global 
assessment allows patients to assess improvement of multiple IBS symptoms, 
however, global assessment cannot show how ramosetron is effective for 
individual IBS symptoms. Therefore, it was deemed beneficial to assess 
“clinically meaningful improvements, focusing on the patient’s chief complaint 
and the severity of major IBS symptoms” in addition to the global assessment.  
 
I firstly explored and examined those variables and I found the 
“improvement in stool consistency” can be a valuable to show how ramosetron 
is effective for individual IBS symptoms. Secondary, I show the results of clinical 
studies used the newly developed variable, “improvement in stool consistency” 
as primary endpoint to evaluate the prospective effect of ramosetron. Finally, I 
discuss and conclude the efficacy variables in clinical study for patients with 
IBS-D. This manuscript referred to List of Published Articles 1 and 2.  
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Chemical name：(-)-(R)-5-[(1-Methyl-1H-indol-3-yl)carbonyl]-4, 5, 6, 7- 
tetrahydro-1H-benzimidazole monohydrochloride 
Molecular formula：C17H17N3O・HCl 
Molecular weight：315.80 
General name：Ramosetron hydrochloride 
Figure 1. Structure of ramosetron. 
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Figure 2. Pathophysiology of IBS and mode of action of ramosetron [Modified 
Figure 7 in reference 21]. 
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Table 1. Primary variables used in IBS clinical trials for the same class drug as 
ramosetron 
Primary 
Endpoint 
Question and Answer  Drug and 
Indication 
Adequate 
relief 
Q. In the past 7 days, have you had 
adequate relief of your IBS pain or 
discomfort? 
A. Binary (Yes/No) 
Alosetron 
(5HT3 
antagonist) 
IBS-D 
[28-30] 
Satisfactory 
relief 
Q. Did you have satisfactory relief of your 
overall IBS symptoms / your abdominal 
discomfort or pain during the last week? 
A. Binary (Yes/No) 
Tegaserod 
(5HT4 
partial 
agonist) 
IBS-C 
[31-34] 
Subject 
global 
assessment 
of relief  
Q. Please consider how you felt during the 
past treatment period in regard to your IBS, 
in particular your overall well-being, and 
symptoms of abdominal pain/discomfort and 
altered bowel habit. Compared to the way 
you usually felt before entering the trial, how 
would you rate your relief of symptoms 
during the past week?   
A. 5-Point Likert scale 
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Table 2. Global assessments used in clinical trials of ramosetron 
Endpoints Question and Answer 
<Primary> 
Global assessment 
of relief of overall 
IBS symptoms 
Q. How would you rate your relief of overall IBS 
symptoms during the past week compared to the 
way you usually felt before entering the trial? 
A. 0, completely relieved; 1, considerably relieved; 2, 
somewhat relieved; 3, unchanged; and 4, worsened 
<Secondary> 
Global assessment 
of relief of 
abdominal 
pain/discomfort 
Q. How would you rate your relief of abdominal 
pain/discomfort during the past week compared to 
the way you usually felt before entering the trial? 
A. 0, completely relieved; 1, considerably relieved; 2, 
somewhat relieved; 3, unchanged; and 4, worsened 
<Secondary> 
Global assessment 
of improvement in 
abnormal bowel 
habits 
Q. How would you rate your relief of abnormal bowel 
habits during the past week compared to the way 
you usually felt before entering the trial? 
A. 0, nearly normalized; 1, considerably relieved; 2, 
somewhat relieved; 3, unchanged; and 4, worsened 
 
Definition of responder 
Weekly 
responders 
Patients with scores of 0 or 1 at each weekly 
evaluation point. 
Monthly 
responders 
Patients who were weekly responders for at least 2 
of the 4 weeks. 
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Chapter 1 Evaluation of Efficacy Variables Focusing on the Patient’s 
Chief Complaint and the Severity of Major IBS Symptoms 
 
A randomized, placebo-controlled, phase IV pilot study was conducted 
to explore and examine efficacy variables focusing on the patient’s chief 
complaint and the severity of major IBS symptoms in male patients with IBS-D 
(Clinicaltrials.gov ID: NCT00918411). The study protocol was designed in 
accordance with the Declaration of Helsinki, Good Clinical Practice (GCP), 
Good Post-marketing Study Practice (GPSP), the applicable laws and 
regulations and was approved by the institutional review board at each site. All 
patients provided written informed consent prior to participating in study-related 
procedures.  
This chapter is divided into 3 parts. First part shows the general 
methods and results in the previously used variables including global 
assessments in this phase IV pilot study, second and third parts concentrate 
on the results focusing on the severity of major IBS symptoms and the patient’s 
chief complaint, respectively [List of Published Articles 1 and 2]. 
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1.1 Synopsis of Phase IV Pilot Study (General Results Including Global 
Assessments) 
 
1.1.1 Background 
This study was conducted from June 2009 to December 2009 at 25 
Japanese centers that have departments of gastroenterology as post marketing 
study, where clinical study was conducted within the approved indication of 
ramosetron. This part showed general methods and results in the previously 
used variables including global assessments in this phase IV pilot study. 
 
1.1.2 Methods 
1) Patient Population 
Male outpatients aged 20–64 years were diagnosed with IBS-D based 
on the Rome III criteria. In the Rome III criteria [9], IBS-D is defined as recurrent 
abdominal pain/discomfort for at least 3 days per month in the preceding 3 
months, in association with two or more of the following: improvement with 
defecation, onset associated with a change in the frequency of stools, and/or 
onset associated with a change in the form (appearance) of stools. Furthermore, 
patients have loose (mushy) or watery stools at least 25% of the time and hard 
or lumpy stools for less than 25% of bowel movements. 
Patients were eligible if they fulfilled the criteria for the last 3 months, 
with symptom onset at least 6 months prior to diagnosis. Organic diseases were 
excluded by colonoscopy or double-contrast barium enema if these 
examinations had not been performed within 5 years. Based on a medical 
interview conducted by the attending physician before provisional registration, 
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patients were excluded if any of the following were evident: a history of 
resection of the stomach, small intestine, or large intestine (excluding 
appendicitis or resection of benign polyps); history or current evidence of 
inflammatory bowel disease; history or current evidence of ischemic colitis, 
concurrent infectious enteritis, hyperthyroidism, hypothyroidism, or other 
diseases that may affect gastrointestinal transit or colonic function; history or 
current evidence of abuse of drugs or alcohol within the previous year; 
malignant tumors; current evidence of severe depression or a severe anxiety 
disorder that could potentially affect the evaluation of study drug efficacy; 
concurrent serious cardiovascular, respiratory, renal, hepatic, gastrointestinal 
(excluding IBS), hematological, or neurological/psychiatric diseases; or a 
history of drug allergies. In addition, patients were excluded if they were using 
drugs or undergoing examinations that could affect the evaluation of study drug 
efficacy; if they had been enrolled in previous clinical studies of ramosetron or 
had taken ramosetron; and if they were participating or had participated in other 
clinical studies within the 12 weeks prior to study initiation. 
Patients satisfying the inclusion and exclusion criteria for typical IBS-D 
symptoms during a 1-week baseline period were enrolled. To avoid enrolling 
patients with extremely mild IBS, severity of abdominal pain/discomfort had to 
exceed mean scores of 0.7 or more assessed daily on a 5-point ordinate 
(numerical rating) scale (0, none; 1, mild; 2, moderate; 3, severe; and 4, 
intolerable). The number of bowel movements had to exceed three times or 
more per week. Stool consistency was assessed with using the Bristol Stool 
Form Scale (BSFS) [9, 10] as follows; type 1, separate hard lumps, like nuts 
(hard to pass); type 2, sausage shaped but lumpy; type 3, like a sausage but 
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with cracks on its surface; type 4, like a sausage or snake, smooth and soft; 
type 5, soft blobs with clear-cut edges (passed easily); type 6, fluffy pieces with 
ragged edges (mushy stool); or type 7, watery, no solid pieces, and entirely 
liquid (Figure 3). Following this classification of stool consistency using the 
BSFS, patients who had either type 1 or type 2 stools were excluded to enroll 
patients who are showing symptoms of IBS-D. Patients who had not used drugs 
or undergone examinations that could affect the evaluation of study drug 
efficacy within 10 days prior to randomization; who recorded all items in the 
patient diary for 5 days or more during the baseline period; and who were not 
judged ineligible for the study according to the clinical laboratory test results 
obtained before the baseline period were randomized and then given treatment. 
 
2) Study Design 
This randomized, placebo-controlled clinical study comprised a 
provisional registration period, a 1-week baseline period, and a 12-week 
treatment period, similar to previous studies [22, 23]. Following the baseline 
period, eligible patients were randomly assigned to 12-week oral treatments 
with placebo or ramosetron 5 µg once daily before breakfast. Visits were 
scheduled at Weeks 2, 4, 8, and 12 (or at discontinuation) to assess treatment 
efficacy, drug compliance, and occurrence of adverse events. Randomization 
was performed in a 1:1 ratio using a block size of four based on a randomization 
list developed by a third-party contract research organization. Placebo tablets 
were externally distinguishable from ramosetron tablets, however, they were 
indistinguishable when packaged in press through pack sheets. Patients were 
prohibited to use drugs or undergo examinations, such as other IBS therapeutic 
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drugs, antidiarrheal drugs, and colonoscopy, that could affect the evaluation of 
study drug efficacy during the treatment period. All patients, investigators, and 
sponsors were blinded until all observations and evaluations were completed, 
the statistical analysis plan was finalized, and all data had been locked.  
 
3) Data Collection 
During the baseline and treatment periods, patients recorded their IBS 
symptoms daily on paper diary cards at bedtime. In the diary, patients recorded 
the BSFS for every bowel movement throughout the study period. Patients 
scored severity on a 5-point ordinate (numerical rating) scale and the duration 
of all continuous abdominal pain/discomfort from Week 1 to Week 4, Week 8 
and Week 12 they had experienced. Urgency and feeling of incomplete 
evacuation were assessed on a binary scale. Every 7 days during the 
treatment period, patients also graded summarized IBS symptoms 
compared with the baseline period on a 5-point ordinate scale as follows: 
relief of overall IBS symptoms and abdominal pain/discomfort (0, completely 
relieved; 1, considerably relieved; 2, somewhat relieved; 3, unchanged; and 4, 
worsened) and improvement in abnormal bowel habits (0, nearly normalized; 1, 
considerably relieved; 2, somewhat relieved; 3, unchanged; and 4, worsened) 
(Table 2). Patients assessed IBS severity using the Japanese version of the 
IBS Severity Index (IBSSI-J) every 4 weeks [35, 36]. Symptoms related to the 
chief complaint were assessed by an investigator at an interview. 
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4) Efficacy Endpoints 
In the monthly responder rates for global assessment of relief of overall 
IBS symptoms, relief of abdominal pain/discomfort and improvement in 
abnormal bowel habits, patients with scores of 0 or 1 at each weekly evaluation 
point were defined as weekly responders, and patients who were weekly 
responders for at least 2 of the 4 weeks were defined as monthly responders 
(Table 2). All adverse events were recorded during the intervention period. 
 
5) Statistical Analysis 
Sample sizes of 60 patients or more (30 patients/group or more) were 
set based on the feasibility of a post marketing study to explore and examine 
the endpoints of the patient’s chief complaint or IBS severity. Statistical analysis 
was performed using SAS Drug Development (ver. 3.4) and PC-SAS (ver. 8.2) 
(SAS Institute Inc., Cary, NC, USA). 
Efficacy analyses included the full analysis set (FAS), which included 
all patients who received at least one dose of the study drug during the 
treatment period and for whom at least one endpoint could be evaluated. Safety 
analyses were performed for all patients who received at least one dose of the 
study drug during the treatment period. 
Monthly responder rates for global assessment are expressed as a 
percentage of responders, and 95% confidence intervals (95% CIs) are 
presented. The treatment groups were compared using the chi-square test with 
a two-sided significance level of 0.05. 
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1.1.3 Results 
1) Overall Study Population 
Figure 4 showed flowchart showing patient progress throughout the 
study. Written informed consent was provided by 115 patients. Of these, 17 
patients dropped out and 98 patients were randomly allocated to the 
ramosetron 5 µg group (n = 47), or the placebo group (n = 51). Ultimately 44 
patients in the ramosetron 5 µg group and 45 patients in the placebo group 
completed the study. The reasons for discontinuation are shown in Figure 4. 
In the placebo group, one patient discontinued by withdrawing consent after 
randomization, with no data, and was excluded from the FAS used in the 
efficacy analyses. The decision to exclude this patient from FAS was taken 
before unblinding, according to the predefined procedure stipulated in the 
study protocol. Demographic and baseline characteristics were similar among 
patients allocated to each group (Table 3). The medication adherence rates 
were 97.6% in the ramosetron 5 µg group and 97.9% in the placebo group. 
 
2) Global Assessment 
The monthly responder rate for global assessment of relief of overall 
IBS symptoms at the last evaluation point was 46.8% (95% CI, 32.1-61.9) in 
the ramosetron 5 µg group and 34.0% (95% CI, 21.2-48.8, P = 0.281) in the 
placebo group (Figure 5). Even though the number of patients enrolled in this 
study is limited, a statistically significant difference between ramosetron and 
placebo was shown in the Month 2 (P = 0.012). Monthly responder rates for 
improvement in abnormal bowel habits in the ramosetron 5 µg group were 
significantly higher than those in the placebo group in the Month 1 (P = 0.015) 
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and the Month 3 (P = 0.048) (Figure 6A). On the other hand, monthly responder 
rates for relief of abdominal pain/discomfort in the ramosetron 5 µg group did 
not show a statistically significant difference between ramosetron and placebo 
at any evaluation point (Figure 6B).  
 
3) Safety 
Safety was evaluated for all 98 patients. Adverse events were 
experienced by 27 patients (57.4%) in the ramosetron 5 µg group and by 20 
patients (39.2%) in the placebo group (Table 4). The incidence of hard stool 
was higher in the ramosetron 5 µg group than in the placebo group, which was 
considered to be caused by the pharmacological action of ramosetron. All the 
events including constipation and hard stool observed in this study were mild 
and improved quickly. There was no occurrence of ischemic colitis or serious 
adverse events. 
 
1.1.4 Discussion 
Despite the limited patient number in this study, statistically significant 
differences between ramosetron and placebo were shown in the monthly 
responder rate for global assessment of relief of overall IBS symptoms in the 
Month 2 and in the monthly responder rates for improvement in abnormal bowel 
habits in the Month 1 and the Month 3. Improvement in bowel habits was shown 
to contribute to improvement of global assessment of relief of overall IBS 
symptoms, as in previous studies [23]. On the other hand, the difference 
between the ramosetron 5 µg and the placebo groups was not evident in the 
monthly responder rate for relief of abdominal pain/discomfort. In the other 
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study with the larger patient number, the ramosetron group showed a 
statistically significant improvement compared to the placebo group in the 
monthly responder rates for relief of abdominal pain/discomfort [23, 25, 37]. It 
is considered that ramosetron can show the effect more clearly on abnormal 
bowel habits than abdominal pain/discomfort. 
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1 
 
Separate hard lumps, like nuts (hard to 
pass) 
2 
 
Sausage-shaped but lumpy 
3 
 
Like a sausage but with cracks in its 
surface 
4 
 
Like a sausage or snake, smooth and soft 
5 
 
Soft blobs with clear-cut edges (passed 
easily) 
6 
 
Fluffy pieces with ragged edges (a mushy 
stool) 
7 Entirely liquid 
Watery, no solid pieces 
 
Figure 3. Bristol Stool Form Scale (BSFS) [9, 10]. 
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Figure 4. Flowchart showing patient progress throughout the study. Reasons 
for dropping out of the study are shown. 
 
 
 
 
 
  
Reasons for dropout
11 did not meet the inclusion or exclusion criteria
2 withdrew consent 
4 other reasons
Study completion
45
Study completion
44
Reasons for discontinuation
1 adverse event
2 withdrew consent
3 adjudged unable to be kept under 
observation
Reasons for discontinuation
2 adverse events
1 other reason
Discontinuation
3
Discontinuation
6
Patients who provided written 
informed consent
115Dropout before or during the 
pre-investigational period
17
Randomized patients
98
Placebo group
51
Ramosetron 5  µg group
47
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Table 3. Demographics and baseline characteristics 
Patient background  
Placebo Ramosetron 5 μg  
P value  
(n = 50)  (n = 47)  
Age (years)  40.9 ± 11.11 41.0 ± 9.31 0.97 
Duration of disease 
103.9 ± 90.27 111.5 ± 129.10 0.738 
(months)  
Severity of abdominal 
1.43 ± 0.58 1.52 ± 0.61 0.481 pain/discomfort  
(0-4)  
Bristol Stool Form Scale 
5.55 ± 0.66 5.52 ± 0.43 0.764 
(1-7)  
Stool frequency  
2.77 ± 1.33 2.44 ± 1.09 0.181 
(times/day)  
 
Data are expressed as mean ± standard deviation. P values were calculated using 
analysis of variance. 
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Figure 5. Monthly responder rates for relief of overall IBS symptoms. Column 
height: responder rate (%). Error bar: 95% CI. P values were calculated using 
the chi-square test. 
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A) 
 
B)  
 
Figure 6. Global assessments. A) Monthly responder rates for improvement in 
abnormal bowel habits. B) Monthly responder rates for relief of abdominal 
pain/discomfort. Column height: responder rate (%). Error bar: 95% CI. P 
values were calculated using the chi-square test.  
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Table 4. Incidence of adverse events 
Event  Placebo  (n = 51)  
Ramosetron 5 μg  
(n = 47)  
All adverse events  20 (39.2%)     27 (57.4%)  
 Gastrointestinal disorders   8 (15.7%)  13 (27.7%)  
Abdominal discomfort  0 (0.0%)  2 (4.3%)  
Constipation  2 (3.9%)  0 (0.0%)  
Hard stool  3 (5.9%)   9 (19.1%)  
Nausea  2 (3.9%)      0 (0.0%)  
 Infections and infestations  4 (7.8%)   5 (10.6%)  
Nasopharyngitis  4 (7.8%)  3 (6.4%)  
Gastroenteritis  0 (0.0%)  2 (4.3%)  
Hepatobiliary disorders  2 (3.9%)  2 (4.3%)  
Hepatic function abnormal  2 (3.9%)  1 (2.1%)  
Skin and subcutaneous tissue disorders  2 (3.9%)  3 (6.4%)  
Dermatitis contact 1 (2.0%)  2 (4.3%)  
 
Data are expressed as number (%). Events with an incidence of ≥ 3% in any of the 
groups are listed. 
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1.2 Evaluation of Efficacy Variables Focusing on the Severity of Major 
IBS Symptoms 
 
1.2.1 Background 
To explore and examine variables that allow evaluation of “clinically 
meaningful improvements, focusing on the severity of major IBS symptoms” 
achieved by this drug, the IBS severity index (IBSSI) was assessed as a new 
measure in this study. The IBSSI is a reliable and well-validated instrument for 
measuring the presence and severity of specific IBS symptoms [35]. Japanese 
versions of the IBS severity index (IBSSI-J) developed and validated by 
Shinozaki et al. are available in Japan [36]. Most studies confirming 
responsiveness of IBSSI were trials aiming at evaluating behavioral 
interventions, and these effects were not compared to placebo. Preliminary 
evaluation was thought to be needed to assess responsiveness of IBSSI-J in 
clinical trials using pharmacological agents. 
 
1.2.2 Methods 
IBSSI-J contains five questions that measure, on a 100-point scale, the 
severity of abdominal pain, the frequency of abdominal pain, the intensity of 
abdominal distention, dissatisfaction with bowel habits, and interference with 
QOL. All five components contribute to the score equally, yielding overall 
scores ranging from 0 to 500. IBS severity is graded as mild (75–174), 
moderate (175–299), or severe (300–500) on the basis of overall scores [35]. 
Whitehead et al. have proposed that at least a 50% reduction from the baseline 
score (≥50% reduction) in IBSSI overall score was considered to constitute 
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clinically meaningful improvement of symptoms [38]. Based on this report, 
patients who had ≥50% reduction in IBSSI-J overall score were defined as 
responders at each evaluation point (ad hoc analysis). Change from baseline 
and percent change from baseline in IBSSI-J score were summarized at each 
evaluation point by treatment group. Treatment comparison used a t-test with 
a two-sided significance level of 0.05. IBSSI score was categorized and 
summarized by whether the subject was a monthly responder on global 
assessment of relief of overall IBS symptoms. 
 
1.2.3 Results 
1) Baseline 
The baseline IBSSI-J overall scores in the ramosetron 5 µg and 
placebo groups were 267.1 ± 98.75 and 246.6 ± 80.52, respectively (Table 5). 
Severity of IBS can be graded as mild (75–174), moderate (175–299), or severe 
(300–500) on the basis of overall IBSSI scores. The proportions of patients with 
moderate severity at baseline were 29.8% in the ramosetron 5 µg group and 
64.0% in the placebo group, with severe grading 46.8% and 22.0%, 
respectively. The respective first-quartile point and third-quartile points were 
180.0 and 355.0 in the ramosetron 5 µg group and 200.0 and 290.0 in the 
placebo group (Table 6). Most patients enrolled in this study were classified as 
moderate to severe. 
Table 6 also showed the baseline score for each of the five components 
included in the IBSSI-J. The highest score was dissatisfaction with bowel habits, 
68.6 ± 25.55 and 66.8 ± 22.78 in the ramosetron 5 µg and placebo groups, 
respectively. Second was interference with QOL (60.0 ± 27.59 and 54.3± 27.39, 
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respectively), followed by frequency of abdominal pain (55.1± 33.87 and 57.4 
± 33.61, respectively). Intensity of abdominal distention showed the lowest 
scores, 35.6 ± 32.25 and 23.8 ± 25.65, respectively. Abdominal pain was 
assessed from the aspects of severity and frequency in the IBSSI-J. Frequency 
of abdominal pain was worse than severity of abdominal pain.   
 
2) Assessment of Treatment Efficacy 
Change in IBSSI-J overall score from baseline (Table 7) was -133.5 ± 
110.72 in the ramosetron 5 µg group and -108.2 ± 94.44 in the placebo group 
(P = 0.228) at the last evaluation point. Differences between the ramosetron 5 
µg and placebo groups adjusted by baseline scores were -11.51 (95% CI, -
43.13-20.11, P = 0.471) at Week 4, -14.39 (95% CI, -47.70-18.93, P = 0.393) 
at Week 8, -16.90 (95% CI, -54.80-21.01, P = 0. 378) at Week 12 and -13.60 
(95% CI, -49.89-22.68, P = 0.459) at the last evaluation point (Figure 7). 
Differences in responder rates for ≥50% reduction in IBSSI-J between in the 
ramosetron 5 µg group and the placebo group were over 10%, except Month 1 
(Figure 8).  
Changes from baseline and percent change from baseline for each five 
component of the IBSSI-J are shown in Tables 7 and 8, respectively. All of each 
five components showed numerically greater change in the ramosetron 5 µg 
group than in the placebo group at all evaluation points (Table 7). Percent 
change from baseline had greater change in the ramosetron 5 µg group than in 
placebo group in all components except intensity of abdominal distention (Table 
8).  
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3) Relationship between IBSSI-J and Global Assessment 
To evaluate clinically meaningful improvement of IBSSI-J, change from 
baseline and percent change from baseline in IBSSI-J score were compared 
by responder/non-responder for global assessment of relief of overall IBS 
symptoms. Mean changes in IBSSI-J overall scores from baseline are 
categorized into ≤ -200, -200 < and ≤ -80, -80 < and ≤ -50, -50 < and ≤ 0, 0 < 
and compared by responder/non-responder for global assessment of relief of 
overall IBS symptoms in Figure 9. Patients who had mean changes in IBSSI-J 
overall scores from baseline exceeding 200 points were more numerous in the 
responder group on global assessment compared to the non-responder group 
(45.9% vs. 11.1% at Week 12). Patients with a change of over 80 points or over 
50 points were also more numerous in the responder group on global 
assessment than in the non-responder group at all evaluation points.  
Similarly, the percent change in IBSSI-J from baseline was categorized 
into ≤ -75%, -75% < and ≤ -50%, -50% < and ≤ -30%, -30% < and ≤ 0% and 
0% < and compared by responder/non-responder for global assessment of 
relief of overall IBS symptoms (Figure 10). The number of patients who had a 
≥ 75% reduction in IBSSI-J overall score was higher in the responder group on 
global assessment than in the non-responder group (35.1% vs. 11.1% at Week 
12). The rate of patients who had a ≥ 50% reduction or ≥ 30% reduction in 
IBSSI-J overall score was also higher in the responder group on global 
assessment than in the non-responder group at all evaluation points.  
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1.2.4 Discussion 
This study showed that most patients enrolled had moderate to severe 
IBS symptoms in the baseline period. The highest score among each 
component was for dissatisfaction with bowel habits. Second was for 
interference with QOL and frequency of abdominal pain. It is well known that 
IBS significantly impairs health related QOL [4]. The patients in this study were 
considered to have impaired QOL. The lowest score of the five components 
was for intensity of abdominal distention. Patients with abdominal distention 
and/or bloating were reported to be more numerous with IBS-C than with IBS-
D [39]. The lowest score of intensity of abdominal distention in IBSSI-J in this 
study might be related to a lower contribution of abdominal distention to IBS 
symptom severity in IBS-D. 
The proportion of patients who had a ≥ 50% reduction in IBSSI-J overall 
score was more than 10% higher in the ramosetron 5 µg group than in the 
placebo group, except Month 1. Although significant results were lacking, 
changes in IBSSI-J score at all evaluation points in the ramosetron 5 µg group 
seems to be superior to that of the placebo group. Francis et al. suggested that 
a decrease of 50 points in IBSSI overall score correlated with improvement in 
clinical symptoms [35]. On the other hand, Whitehead et al. have proposed that 
≥ 50% reduction in IBSSI overall score from the baseline score was considered 
to constitute clinically meaningful improvement of symptoms [38]. In this study, 
other categorization was evaluated to find “clinically meaningful improvements” 
by pharmacological agents, and compared responder/non-responder for global 
assessment of relief of overall IBS symptoms. In Francis’s report, mean change 
of IBSSI from baseline to 3 months later was significantly greater in the patients 
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who became clinically considerably better than little changed (change in score: 
83 vs. 6) [35]. Based on their reports, -50 and -80 points reductions were 
selected. The baseline IBSSI-J overall scores in our ramosetron 5 µg and 
placebo groups were 267.1 ± 98.75 and 246.6 ± 80.52, respectively (Table 5). 
Because IBS severity is rated as No symptoms (0-74), a -200 points reduction 
was set as the score at which the symptoms were eliminated. Similarly, in 
addition to 50% reduction, 3/4 and 1/3 reduction categories were examined to 
explore the clinical meaningful change. This study showed patients who had 
changes in their overall IBSSI-J scores from baseline of over 50 points were 
more numerous in the monthly responder group based on global assessment 
of relief of overall IBS symptoms than in the non-responder group. This finding 
is in accordance with the results of Francis et al. [35]. The proportion of patients 
who had a ≥ 50% reduction in IBSSI-J overall score was also higher in the 
responder group on global assessment (24/37, 64.9%) than in the non-
responder group (18/54, 33.3%) at Week 12. The studies by Francis et al. and 
Whitehead et al. were trials aiming to evaluate behavioral interventions, and 
these effects were not compared to placebo. In patients with IBS-C, it was 
recently reported that linaclotide, guanylate cyclase-C agonist, showed a 
statistically significantly higher change in IBSSI overall score from baseline as 
well as in the percentage of patients with ≥ 50% reduction in IBSSI overall score 
compared to placebo [40]. Nevertheless, those data suggest that the IBSSI 
could be used for measuring response to pharmacological agents for patients 
with IBS-C; there are little data used for measuring the response of patients 
with IBS-D. Differences between ramosetron and placebo in this study were not 
evident. This study was the first trial to use the IBSSI-J to measure the response 
31 
 
to pharmacological agents in patients with IBS-D. Further investigation will be 
needed to use this questionnaire as a primary endpoint in clinical studies 
related to the development of pharmacological agents for IBS-D patients. 
In this study, the monthly responder group with respect of global 
assessment of relief of overall IBS symptoms showed a greater change in the 
IBSSI-J overall score and percent change from baseline than did the non-
responder group. This study thus revealed that responses on global 
assessment were correlated with improvement in IBSSI-J, suggesting that 
global assessment reflects improvement of the symptom severity of patients 
with IBS-D.  
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Table 5. Baseline characteristics classified by IBSSI-J severity 
Baseline 
Placebo 
(n = 50) 
Ramosetron 5 μg 
(n = 47) 
P value 
IBSSI-J overall score 246.6 ± 80.52 267.1 ± 98.75 0.264 
No symptoms (0-74) 0 (0.0%) 1 (2.1%) - 
Mild (75-174) 7 (14.0%) 10 (21.3%) - 
Moderate (175-299) 32 (64.0%) 14 (29.8%) - 
Severe (300-500) 11 (22.0%) 22 (46.8%) - 
 
Data are expressed as mean ± standard deviation. P values were calculated using 
analysis of variance. 
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Table 6. Baseline IBSSI-J score   
  N Mean ± SD  Min Max Median First-quartile  Third-quartile  t-test  
Overall score Placebo 50 246.6 ± 80.52  80 410 245 200 290 t = -1.123, df = 95,  
P = 0.264  Ramosetron 5 μg 47 267.1 ± 98.75  60 440 275 180 355 
Severity of abdominal pain  Placebo 50 44.3 ± 26.71  0 100 47.5 20 70 t = -0.647, df = 95,  
P = 0.519  Ramosetron 5 μg 47 47.8 ± 26.70  0 90 50 30 70 
Frequency of abdominal 
pain  
Placebo 50 57.4 ± 33.61  0 100 60 30 90 t = 0.335, df = 95,  
P = 0.739  Ramosetron 5 μg 47 55.1 ± 33.87  0 100 60 30 90 
Intensity of abdominal 
distention  
Placebo 50 23.8 ± 25.65  0 80 17.5 0 50 t = -2.007, df = 95,  
P = 0.048  Ramosetron 5 μg 47 35.6 ± 32.25  0 100 30 0 60 
Dissatisfaction with bowel 
habits  
Placebo 50 66.8 ± 22.78  20 100 60 50 90 t = -0.361, df = 95,  
P = 0.719  Ramosetron 5 μg 47 68.6 ± 25.55  0 100 70 50 90 
Interference with QOL Placebo 50 54.3 ± 27.39  0 100 55 30 80 
t = -1.013, df = 95,  
P = 0.314 Ramosetron 5 μg 47 60.0 ± 27.59  0 100 60 40 80 
 
Data are expressed as mean ± standard deviation (SD). P values were calculated using analysis of variance. 
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Table 7. Change in each IBSSI-J component score from baseline at each evaluation point 
 
Week 4  Week 8  Week 12  Last point  
Placebo  Ramosetron   5 μg  Placebo  
Ramosetron    
5 μg  Placebo  
Ramosetron    
5 μg  Placebo  
Ramosetron    
5 μg  
Mean ± SD 
P value  
Mean ± SD 
P value  
Mean ± SD 
P value  
Mean ± SD 
P value  
Mean ± SD 
P value  
Mean ± SD 
P value  
Mean ± SD 
P value  
Mean ± SD 
P value  
N  48  46  49  44  47  44  50  47  
Overall scores   -75.0 ± 81.52   -95.9 ± 105.12  
(P = 0.283)  
 -103.0 ± 81.81  -130.6 ± 114.27  
(P = 0.181)  
 -110.3 ± 97.04  -137.0 ± 113.18  
(P = 0.231)  
 -108.2 ± 94.44  -133.5± 110.72  
(P  = 0.228)  
Severity of abdominal 
pain  
 -15.3 ± 25.18  -17.0 ± 25.15  
(P = 0.743)  
 -21.4 ± 28.46  -24.3 ± 27.41  
(P = 0.625)  
 -21.9 ± 30.42  -26.6 ± 27.01  
(P = 0.439)  
 -21.9 ± 29.76  -26.1 ± 26.41  
(P = 0.467)  
Frequency of abdominal 
pain  
 -16.5 ± 25.89  -20.0 ± 32.52  
(P = 0.560)  
 -24.7 ± 29.38  -26.6 ± 35.04  
(P = 0.777)  
 -25.1 ± 32.56  -28.2 ± 35.13  
(P = 0.666)  
 -24.6 ± 31.77 -28.1 ± 33.98  
(P = 0.603)  
Intensity of abdominal 
distension  
 -9.7 ± 23.13  -16.3 ± 27.68  
(P = 0.214)  
 -12.2 ± 24.54 -17.8 ± 26.66  
(P = 0.295)  
 -11.5 ± 25.83  -16.6 ± 29.88  
(P = 0.385)  
 -10.8 ± 25.26  -16.3 ± 29.22  
(P = 0.325)  
Dissatisfaction with bowel 
habits  
 -16.2 ± 31.23  -20.8 ± 28.18  
(P = 0.454)  
 -19.2 ± 33.55  -31.4 ± 29.88  
(P = 0.067)  
 -25.1 ± 33.57  -33.4 ± 31.50  
(P = 0.230)  
 -24.8 ± 33.84  -32.5 ± 30.63  
(P = 0.243)  
Interference with QOL   -17.3 ± 27.76  -21.8 ± 29.94  
(P = 0.454)  
 -25.5 ± 27.75  -30.5 ± 34.84  
(P = 0.445)  
 -26.7 ± 28.67  -32.2 ± 32.53  
(P = 0.396)  
 -26.1 ± 28.04 -30.6 ± 32.44  
(P = 0.470)  
 
Data are expressed as mean ± standard deviation (SD). P values were calculated using analysis of variance.  
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Table 8. Percent change in each IBSSI-J component score from baseline at each evaluation point 
 
Week 4  Week 8  Week 12  Last point  
Placebo  Ramosetron   5 μg  Placebo  
Ramosetron    
5 μg  Placebo  
Ramosetron    
5 μg  Placebo  
Ramosetron    
5 μg  
Mean ± SD 
P value  
Mean ± SD 
P value  
Mean ± SD 
P value  
Mean ± SD 
P value  
Mean ± SD 
P value  
Mean ± SD 
P value  
Mean ± SD 
P value  
Mean ± SD 
P value  
N  48  46  49  44  47  44  50  47  
Overall scores   -27.2 ± 29.72   -31.2 ± 40.08  
(P = 0.589)  
 -40.7 ± 26.73  -43.8 ± 35.33  
(P = 0.639)  
 -42.7 ± 32.71  -48.9 ±34.51  
(P = 0.379)  
 -42.6 ± 31.98  -47.8± 33.94  
(P = 0.432)  
Severity of abdominal 
pain  
 -20.6 ± 62.3  -40.5 ± 33.55  
(P = 0.070)  
 -36.7 ± 53.26  -54.2 ± 42.23  
(P = 0.102)  
 -32.9 ± 91.13  -58.3 ± 35.56  
(P = 0.103)  
 -34.4 ± 88.82  -57.5 ± 36.13  
(P = 0.117)  
Frequency of abdominal 
pain  
 -27.2 ± 43.33  -36.0 ± 44.90  
(P = 0.361)  
 -44.5 ± 46.43  -49.1 ± 50.54  
(P = 0.666)  
 -46.3 ± 50.08  -51.2 ± 49.21  
(P = 0.653)  
 -46.8 ± 49.55 -51.5 ± 48.2  
(P = 0.653)  
Intensity of abdominal 
distension  
 -44.6 ± 55.51  -27.4 ± 91.19  
(P = 0.368)  
 -56.3 ± 51.91 -44.5 ± 76.81  
(P = 0.479)  
 -47.5 ± 61.58  -40.9 ± 62.39  
(P = 0.679)  
 -44.5 ± 65.79  -40.1 ± 60.93  
(P = 0.779)  
Dissatisfaction with bowel 
habits  
 -11.9 ± 65.32  -25.1 ± 41.22  
(P = 0.252)  
 -15.7 ± 77.16  -39.0 ± 39.47  
(P = 0.078)  
 -29.3 ± 52.81  -43.4 ± 48.44  
(P = 0.190)  
 -28.7 ± 52.17  -42.4 ± 47.01  
(P = 0.183)  
Interference with QOL   -11.1 ± 115.81  -31.3 ± 45.69  
(P = 0.277)  
 -28.6 ± 116.7  -44.5 ± 51.7  
(P = 0.411)  
 -22.2 ± 174.64  -49.0 ± 43.65  
(P = 0.330)  
 -24.0 ± 169.49 -47.1 ± 46.31  
(P = 0.374)  
 
Data are expressed as mean ± standard deviation (SD). P values were calculated using analysis of variance. 
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Figure 7. Change in IBSSI-J overall scores from baseline, adjusted by baseline 
score. Column height: the values adjusted using the baseline score as a 
covariate. Error bar: 95% CI. P values were calculated using analysis of 
covariance with the treatment group as a factor and baseline score as a 
covariate.  
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Figure 8. Responder rates for at least a 50% reduction from baseline in 
IBSSI-J overall score. Column height: responder rates (%). Error bar: 95% 
CI. P values were calculated using the chi-square test. 
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Figure 9. Relationship between changes in IBSSI-J overall scores and global 
assessment. Changes in IBSSI-J overall scores from baseline were compared 
by responder (R) /non-responder (NR) for global assessment of relief of overall 
IBS symptoms. Mean changes in IBSSI-J overall scores from baseline were 
categorized into the following groups: ≤ -200, -200 < and ≤ -80, -80 < and ≤  
-50, -50 < and ≤ 0, and 0 <. 
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Figure 10. Relationship between percent change in IBSSI-J overall score and 
global assessment. Percent change in IBSSI-J overall score from baseline was 
compared by responder (R) /non-responder (NR) for global assessment of relief 
of overall IBS symptoms. Percent change in IBSSI-J from baseline was 
categorized into the following groups: ≤ -75%, -75% < and ≤ -50%, -50% < and 
≤ -30%, -30% < and ≤ 0%, and 0% <. 
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1.3 Evaluation of Efficacy Variables Focusing on the Patient’s Chief 
Complaint 
 
1.3.1 Background 
Because IBS is a syndrome, most previous studies to develop agents 
for IBS have used global assessments as primary endpoints [22-26, 37, 41]. 
Individual symptoms of IBS were assessed as secondary endpoints. The most 
bothersome IBS symptoms reported in clinical trials of alosetron, the same 
class drug as ramosetron, were abdominal pain and urgency [30, 42]. However, 
there were no data regarding the chief complaint in previous clinical trials of 
ramosetron. To explore and examine variables that allow evaluation of 
“clinically meaningful improvements, focusing on the patient’s chief complaint,” 
the chief complaint and its relief by this study drug were assessed in this study. 
 
1.3.2 Methods 
Symptoms related to the chief complaint were clarified by an 
investigator at an interview. The investigator scored the most bothersome IBS 
symptoms the patient had (none, abdominal pain/discomfort, stool form, stool 
frequency, urgency, feeling of incomplete evacuation, and others) as symptoms 
of the chief complaint at the Week 0, 4, 8, and 12 (or at discontinuation) visits. 
The investigator also scored any improvement in symptoms of the chief 
complaint the patients had before administration compared to the baseline 
period on a 5-point ordinate scale (0, completely relieved; 1, considerably 
relieved; 2, somewhat relieved; 3, unchanged; and 4, worsened) at the Week 
4, 8, and 12 (or at discontinuation) visits. The treatment groups were compared 
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using the Wilcoxon rank sum test with a two-sided significance level of 0.05. As 
an ad hoc analysis, patients with scores of 0 (completely relieved) or 1 
(considerably relieved) at each evaluation point were defined as responders, 
with relief of their chief complaint. Patients with missing data were regarded as 
non-responders. Chi-square test was used for treatment comparison. BSFS 
was evaluated using the t-test. 
Improvement in stool consistency was analyzed for the patients with 
baseline BSFS scores over 5, in an ad hoc manner. Patients with weekly mean 
BSFS scores of 3 to 5 during a 1-week of the treatment period and a decrease 
of one or more points in mean BSFS scores from the baseline period were 
defined as weekly responders. Patients who were weekly responders for at 
least 2 of the 4 weeks in a 1-month were considered monthly responders. If 
more than 2 daily scores were missing during any week of the study period, the 
mean score for that week was defined as missing. Patients with missing mean 
BSFS scores were regarded as weekly non-responders. The treatment group 
were compared using a chi-square test. 
 
1.3.3 Results 
1) Baseline 
Table 9 showed the symptoms of the chief complaint that patients had 
before administration. Abdominal pain/discomfort, stool form, and stool 
frequency were key symptoms for the patients enrolled in this study. The 
proportion of patients whose chief complaint was abdominal pain/discomfort 
was 34.0% in the ramosetron 5 µg group and 42.0% in the placebo group. 
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Regarding stool form and stool frequency, key symptoms among bowel habit 
abnormalities, the respective proportion of patients was 19.1% and 25.5% in 
the ramosetron 5 µg group and 18.0% and 20.0% in the placebo group. 
 
2) Assessment of Treatment Efficacy 
Improvement in the symptoms of the chief complaint that patients had 
before administration was assessed on a 5-point ordinate scale at every visit 
(Figure 11). Patients with scores of 0 (completely relieved) or 1 (considerably 
relieved) at each evaluation point were defined as responders (Figure 12). 
Responder rates for improvement in the symptoms of the chief complaint that 
patients had before administration were 53.2% (95% CI, 38.1–67.9 at the last 
point) in the ramosetron 5 µg group and 42.0% (95% CI, 28.2–56.8 at the last 
point, P = 0.368) in placebo. The difference between placebo and ramosetron 
was over 10% at all evaluation points. Figure 13 showed improvement in the 
symptoms of each chief complaint that patients had before administration. 
Regarding stool form, the number of patients who had completely relieved or 
considerably relieved symptoms in the ramosetron 5 µg group increased in a 
time-dependent manner. Almost all patients showed completely relieved 
(12.5%) or considerably relieved (75%) symptoms in relation to stool form in 
the ramosetron 5 µg group at Week 12. The difference between ramosetron 
and placebo was greatest with respect to stool form. Improvement in the 
ramosetron 5 µg group compared to placebo was also observed with respect 
to stool frequency at all evaluation points. Among patients who had abdominal 
pain/discomfort as a symptom of their chief complaint before administration, 
patients in the ramosetron 5 µg group showed numerous improvements at 
43 
 
Weeks 4 and 8 compared to patients in the placebo group with the same 
symptoms, however, the difference between ramosetron and placebo was not 
clear at Week 12 and at the last evaluation point. 
 
3) Relationship between Improvement in Chief Complaint and Global 
Assessment 
To evaluate clinical meaningful improvement of the chief complaint, 
improvement in the chief compliant that patients had before administration was 
compared by responder/non-responder for global assessment of relief of 
overall IBS symptoms (Figure 14). Regarding stool form, patients who reported 
that they were completely relieved or considerably relieved in the improvement 
of chief complaint were more numerous in the responder group on global 
assessment compared to the non-responder group (8/9, 88.9% vs. 3/9, 33.3% 
at the last point). The same results were observed for abdominal 
pain/discomfort (11/14, 78.6% vs. 8/23, 34.8% at the last point) and stool 
frequency (7/9, 77.8% vs. 1/13, 7.7% at the last point). 
 
4) Weekly Changes in Stool Form 
When compared to placebo, the greatest improvement in symptoms of 
the chief complaint that patients had before administration in the ramosetron 5 
µg group was shown in stool form. Weekly change in BSFS scores were shown 
in Figure 15. BSFS scores were significantly lower in the ramosetron 5 µg group 
(4.36 ± 1.195 at the last point) than in the placebo group (4.85 ± 0.890 at the 
last point, P = 0.027) throughout the treatment period, except at Week 6. No 
significant difference was observed between the ramosetron 5 µg group and 
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the placebo group regarding changes in the severity of abdominal 
pain/discomfort and stool frequency from baseline per week. 
 
5) Ad hoc Analysis for Newly Developed Variable “Improvement in Stool 
Consistency” 
Because stool form was considered to be the most effective symptom 
for demonstrating if ramosetron brought about a clinically meaningful 
improvement, monthly responder rates for improvement in stool consistency 
were analyzed ad hoc for patients with baseline BSFS scores over 5 (Figure 
16). Patients with weekly mean BSFS scores of 3 to 5 during a 1-week of the 
treatment period and a decrease of one or more points in mean BSFS scores 
from the baseline period were considered as clinically meaningful improvement 
in stool consistency. Responder rates for improvement in stool consistency 
were 40.5% (95% CI, 25.6–56.7 at the last point) in the ramosetron 5 µg group 
and 18.9% (95% CI, 8.0–35.2 at the last point, P = 0.067) in the placebo group. 
The difference between placebo and ramosetron was over 19% at all evaluation 
points. 
 
1.3.4 Discussion 
IBS is characterized by two major IBS symptoms, abdominal 
pain/discomfort and abnormal bowel habits. Regarding the chief complaint that 
patients had before administration, 34.0% of the patients in the ramosetron 5 
µg group and 42.0% of the patients in the placebo group reported abdominal 
pain/discomfort. The remaining patients complained of abnormal bowel habits, 
including abnormal stool form, increased stool frequency, defecation urgency, 
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and a feeling of incomplete evacuation. Of these, the highest proportions were 
related to stool form (19.1% in the ramosetron 5 µg group and 18.0% in the 
placebo group) and stool frequency (25.5% in the ramosetron 5 µg and 20.0%, 
in the placebo group). Stool form and stool frequency were thus considered to 
be the most important chief complaints among the bowel habit abnormalities. 
When compared to placebo, the greatest improvement in symptoms of the chief 
complaint that patients had before administration in the ramosetron 5 µg group 
was shown in stool form. This result was consistent with the finding that BSFS 
scores were significantly lower in the ramosetron 5 µg group than in the placebo 
group.  
This study, therefore, found that ramosetron acted most effectively on 
stool consistency. Stool consistency correlates with colonic transit time [43, 44] 
and can be a good indicator of bowel function. In rats, ramosetron also clearly 
reduced stress-induced diarrhea and accelerated defecation caused by CRH 
[15, 19]. To show how ramosetron is effective for individual IBS symptoms, 
focusing on stool consistency was considered to be acceptable in light of the 
drug’s pharmacological mechanism. 
Stool form is considered to be the most effective symptom for 
demonstrating if ramosetron brought about a clinically meaningful improvement. 
However, if the effect of ramosetron on stool consistency is excessive, it leads 
to constipation. In developing agents to treat IBS-D, it is insufficient to only 
compare the change in stool form from baseline between ramosetron and 
placebo. It is also considered important to define a clinically meaningful 
“improvement in stool consistency”. BSFS scores of 3 to 5 are recognized as 
normal stool form in the Rome III criteria. Therefore, weekly mean BSFS scores 
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of 3 to 5 during a 1-week of the treatment period and a decrease of one or more 
points in mean BSFS scores from the baseline period are considered as 
clinically meaningful improvement in stool consistency. I thus defined monthly 
responder rates in respect to improvement in stool consistency (Table 10) and 
revealed greater responder rates in the ramosetron 5 µg group compared to 
the placebo group by ad hoc analysis. 
In this study, improvement in the chief complaint the patient had before 
administration was more frequent in the responder group in global assessment 
of relief of overall IBS symptoms compared to the non-responder group. 
Improvement of each IBS symptom seems to be related to improvement of 
overall IBS symptoms. These relationships were obtained not only for stool 
form, but also for abdominal pain/discomfort and stool frequency. 
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Table 9. Chief complaint that patients had before administration of the study 
drug 
Chief complaint: symptoms  
before administration  
Placebo 
(n = 50)  
Ramosetron 5 μg  
(n = 47)  
None  0 (0.0%)  0 (0.0%)  
Abdominal pain/discomfort  21 (42.0%)  16 (34.0%) 
Stool form   9 (18.0%)   9 (19.1%) 
Stool frequency  10 (20.0%)  12 (25.5%) 
Urgency   6 (12.0%)   7 (14.9%)  
Feelings of incomplete evacuation  4 (8.0%)  3 (6.4%)  
Others  0 (0.0%) 0 (0.0%) 
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Figure 11. Improvement in symptoms of the chief complaint that patients had 
before administration of the study drug. 
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Figure 12. Responder rate for improvement in symptoms of the chief complaint 
that patients had before administration of the study drug. Height: responder rate 
(%). Error bar: 95% CI. P values were calculated using the chi-square test.  
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Figure 13. Improvement in symptoms of each chief complaint that patients 
had before administration of the study drug. 
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Figure 14. Relationship between improvement in chief compliant and global 
assessment. Improvement in chief compliant that patients had before 
administration was compared between responders and non-responders for 
global assessment of relief of overall IBS symptoms. 
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Figure 15. Weekly changes in BSFS scores. Line graph: means ± standard 
deviation. P values were calculated using the t-test, as follows: ***P < 0.001, 
**P < 0.01 and *P < 0.05. 
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Figure 16. Monthly responder rates for improvement in stool consistency. 
Height: responder rate (%). Error bar: 95% CI. P values were calculated using 
the chi-square test.  
 
 
  
54 
 
Table 10. Definition of responder of “improvement in stool consistency” 
Weekly responder Weekly mean BSFS scores of 3 to 5 during a 1-week 
of the treatment period and a decrease of one or more 
points in mean BSFS scores from the baseline period. 
Monthly responder Patients who were weekly responders for at least 2 of 
the 4 weeks in a 1-month. 
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Chapter 2 Evaluation of Efficacy of Ramosetron Using Improvement 
in Stool Consistency 
 
In this chapter, I summarized the results of clinical studies, which used 
the newly developed variable, “improvement in stool consistency” as the 
primary endpoint to evaluate the prospective effect of ramosetron [25, 37]. 
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2.1 Phase IV Study of Ramosetron in Male Patients with IBS-D 
 
2.1.1 Background 
A randomized, placebo-controlled, phase IV study was conducted to 
evaluate the prospective effect of ramosetron with the improvement in stool 
consistency as the primary endpoint (Clinicaltrials.gov ID: NCT01225237) [37]. 
This study was conducted from October 2010 to August 2011 at 52 centers that 
have departments of gastroenterology. The study protocol was designed in 
accordance with the Declaration of Helsinki, GCP, GPSP, the applicable laws 
and regulations and was approved by the institutional review board at each site. 
All patients provided written informed consent prior to participating in study-
related procedures. 
 
2.1.2 Methods 
1) Patient Population 
This study comprised a provisional registration period, a 1-week 
baseline period, and a 12-week treatment period, similar to previous studies 
[22, 23]. Male outpatients aged 20–64 years were diagnosed according to the 
Rome III criteria. Patients satisfying the inclusion and exclusion criteria were 
monitored during a 1-week baseline period in which data on severity of 
abdominal pain/discomfort and stool consistency were collected to ensure that 
patients met the criteria. Patients who had not used drugs or undergone 
examinations that could affect the evaluation of study drug efficacy within 10 
days prior to randomization; who recorded all items in the patient diary for ≥5 
days during the baseline period; who had mean severity scores of abdominal 
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pain/discomfort of ≥0.7 during the baseline period (a 5-point ordinate scale); in 
whom no type 1 or 2 stool form, as scored by BSFS, was recorded during the 
baseline period; who had bowel movements for ≥5 days, with a mean score of 
>5 on BSFS during the baseline period; and who were not judged ineligible for 
the study according to the clinical laboratory test results received before the 
baseline period were randomized and successively administered treatment. 
 
2) Study Design 
Following the baseline period, eligible patients were randomly assigned 
to 12-week oral treatments with placebo or ramosetron 5 μg once daily before 
breakfast. Visits were scheduled at Weeks 2, 4, 8, and 12 (or at discontinuation) 
to assess treatment efficacy, drug compliance, and occurrence of adverse 
events. Randomization was performed in a 1:1 ratio using a block size of 4 with 
a web-based randomization system. All patients, investigators, and sponsors 
were blinded until all observations and evaluations were completed, statistical 
analysis plans were finalized, and all data had been entered. 
 
3) Data Collection 
During the baseline and treatment periods, patients recorded their IBS 
symptoms daily on paper diary cards at bedtime, and electronically entered 
data into a database daily using an interactive voice response system to 
support the completion of data entry in the paper diary cards. In the diary, 
patients recorded the BSFS types and stool frequencies and scored the 
severity of their abdominal pain/discomfort. Urgency and feeling of incomplete 
evacuation were assessed on a binary scale. Every 7 days during the treatment 
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period, patients also graded summarized IBS symptoms compared with the 
baseline period on a 5-point ordinate scale.  
 
4) Efficacy Endpoints 
The primary endpoint was monthly responder rates for improvement in 
stool consistency in the Month 1. Patients with weekly mean BSFS scores of 3 
to 5 during a 1-week of the treatment period and a decrease of one or more 
points in mean BSFS scores from the baseline period were defined as weekly 
responders. Patients who were weekly responders for at least 2 of the 4 weeks 
in a 1-month were considered monthly responders (Table 10). If more than 2 
daily scores were missing during any week of the study period, the mean score 
for that week was defined as missing. Patients with missing mean BSFS scores 
were regarded as weekly non responders. 
Secondary endpoints included monthly responder rates for global 
assessment of relief of overall IBS symptoms, relief of abdominal 
pain/discomfort, and improvement in abnormal bowel habits. Patients with 
scores of 0 or 1 at each weekly evaluation point were defined as weekly 
responders, and patients who were weekly responders for at least 2 of the 4 
weeks in a 1-month were considered to be monthly responders (Table 2). 
Scales measuring IBS symptoms, including severity of abdominal 
pain/discomfort, BSFS, stool frequency, urgency and feeling of incomplete 
evacuation and IBS-QOL were established for the secondary endpoints. All 
adverse events were recorded during the intervention period.  
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5) Statistical Analysis 
Statistical analysis was performed using SAS Drug Development (ver. 
3.4) and PC-SAS (ver. 9.1.3) (SAS Institute Inc., Cary, NC, USA). Sample sizes 
of 260 patients (130 patients/group) were calculated to provide 90% power to 
detect a 19.2% difference in monthly responder rates of improvement in stool 
consistency during the Month 2 between the 2 groups (18.9% and 38.1% for 
the placebo and ramosetron groups, respectively, Figure 16) based on the 
phase IV pilot study (Clinicaltrials.gov ID: NCT00918411), using the chi-square 
test with a two-sided significance level of 0.05. 
Efficacy analyses included the FAS, which included all patients who 
received at least one dose of the study drug during the treatment period and for 
whom at least one endpoint could be evaluated. Safety analyses were 
performed for all patients who received at least 1 dose of the study drug during 
the treatment period. 
Monthly responder rates for improvement in stool consistency and 
global assessments are expressed as a percentage of responders, and 95% 
CIs are presented. The treatment groups were compared using the chi-square 
test with a two-sided significance level of 0.05. Other monthly responder rate 
parameters were similarly analyzed. BSFS were evaluated by using the t-test. 
Adverse events were evaluated using Fisher’s exact test. 
 
2.1.3 Results 
1) Improvement in Stool Consistency 
The ramosetron 5 µg group showed significantly higher improvement 
in stool consistency compared to the placebo group at all evaluation points 
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(Figure 17). Monthly responder rates in the Month 1 (primary endpoint) were 
50.3% (95% CI, 42.0–58.7) and 19.6% (95% CI, 13.5–26.9) in the ramosetron 
and placebo groups, respectively (difference, 30.7%; 95% CI, 20.4–41.1; P < 
0.001). In the last evaluation points, responder rates were 44.2% (95% CI, 
36.0–52.6) and 25.0% (95% CI, 18.3–32.8), respectively (difference, 19.2%; 
95% CI, 8.6–29.9; P < 0.001)  
 
2) Global Assessment 
Monthly responder rates for global assessment of relief of overall IBS 
symptoms were significantly higher in the ramosetron 5 µg group than in the 
placebo group at all evaluation points (Figure 18). Monthly responder rates for 
improvement in abnormal bowel habits (Figure 19A) and relief of abdominal 
pain/discomfort (Figure 19B) were also significantly higher in the ramosetron 5 
µg group than in the placebo group at all evaluation points.  
 
3) Weekly Changes in Stool Form 
Weekly BSFS scores were significantly lower in the ramosetron 5 µg 
group (4.9 ± 0.8 at Week 1 and 4.8 ± 1.0 at the last point) than those in the 
placebo group (5.4 ± 0.7 at Week 1 and 5.2 ± 0.8 at the last point, P < 0.001) 
throughout the treatment period (Figure 20). 
 
4) Safety 
The incidence of hard stools was significantly higher in the ramosetron 
5 µg group (8.2%) than in the placebo group (1.3%, P = 0.006) (Table 11). The 
ramosetron 5 µg group also induced constipation in 3.4% patients. However, 
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the incidence was not significantly higher than that in the placebo group (0.7%). 
All episodes of constipation and hard stools in the ramosetron 5 µg group, 
assumed to be caused by the pharmacological actions of ramosetron, were 
classified as mild and resolved early without using rescue drugs.  
 
2.1.4 Discussion 
This study examined the effects of ramosetron on stool consistency in 
male IBS-D patients, testing the hypothesis that ramosetron 5 µg is superior to 
placebo in improving stool consistency. As a result, the ramonsetron 5 µg group 
showed significantly higher monthly responder rates for improvement in stool 
consistency compared to the placebo group in male patients with IBS-D. The 
ramosetron 5 µg group also showed significant improvement of global 
assessment and individual IBS symptoms including stool form. This study’s 
results indicate that based on the pharmacologic profile of ramosetron, 
improvement in stool consistency is the best endpoint for studies of ramosetron 
in patients with IBS-D.  
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Figure 17. Monthly responder rates for improvement in stool consistency 
[Modified Figure 2 in reference 37]. Column height: responder rate (%). Error 
bar: 95% CI. P values were calculated using the chi-square test. 
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Figure 18. Monthly responder rates for relief of overall IBS symptoms [Modified 
Figure 3A in reference 37]. Column height: responder rate (%). P values were 
calculated using the chi-square test. 
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A) 
 
B) 
 
Figure 19. A) Monthly responder rate for improvement in abnormal bowel habits 
[Modified Supplementary Figure 2 in reference 37]. B) Monthly responder rates 
for relief of abdominal pain/discomfort [Modified Figure 3B in reference 37]. 
Column height: responder rate (%). P values were calculated using the chi-
square test.  
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Figure 20. Weekly changes in BSFS scores [Modified Figure 3C in reference 
37]. Line graph: means ± SD. P values were calculated using the t-test, as 
follows: **P < 0.001 and *P < 0.01. 
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Table 11. Incidence of adverse events [Modified Table 2 in reference 37] 
Event 
Placebo 
(n = 149) 
Ramosetron 5 μg 
(n = 147) 
P value 
All adverse events 77 (51.7%) 69 (46.9%) 0.48 
Blood and lymphatic system 
disorders 
1 (0.7%) 3 (2.0%) 0.37 
Anemia 1 (0.7%) 3 (2.0%) 0.37 
Gastrointestinal disorders 21 (14.1%) 21 (14.3%) 1.00 
Constipation 1 (0.7%) 5 (3.4%) 0.12 
Hard stool 2 (1.3%) 12 (8.2%) 0.01 
Hepatobiliary disorders 5 (3.4%) 3 (2.0%) 0.72 
Hepatic dysfunction 5 (3.4%) 3 (2.0%) 0.72 
Infections and infestations 39 (26.2%) 29 (19.7%) 0.21 
Gastroenteritis 2 (1.3%) 4 (2.7%) 0.45 
Nasopharyngitis 25 (16.8%) 20 (13.6%) 0.52 
Investigations 21 (14.1%) 13 (8.8%) 0.20 
Increased serum alanine 
aminotransferase 
7 (4.7%) 3 (2.0%) 0.34 
Increased serum bilirubin 3 (2.0%) 3 (2.0%) 1.00 
Nervous system disorders 4 (2.7%) 4 (2.7%) 1.00 
Headache 1 (0.7%) 3 (2.0%) 0.37 
 
Data are expressed as numbers (%). Events with an incidence of ≥2% in the ramosetron 
5 μg group are listed. P values were calculated by using Fisher's exact test. 
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2.2 Phase III Study of Ramosetron in Female Patients with IBS-D 
 
2.2.1 Background 
A randomized, placebo-controlled, phase III study was conducted to 
determine whether ramosetron reduces symptoms of IBS-D in women 
(Clinicaltrials.gov ID: NCT01870895) [25]. It was deemed important to show 
how ramosetron is effective for individual IBS symptoms in addition to the 
improvement of overall symptoms of the syndrome. Monthly responder rates 
for improvement in stool consistency were assessed as co-primary endpoints 
with monthly responder rates for global assessment of relief of overall IBS 
symptoms. This study was conducted from February 2013 to February 2014 at 
70 centers that have departments of gastroenterology. The study protocol was 
designed in accordance with the Declaration of Helsinki, GCP, the applicable 
laws and regulations and was approved by the institutional review board at 
each site. All patients provided written informed consent prior to participating 
in study-related procedures.  
 
2.2.2 Methods 
1) Patient Population 
This study comprised a provisional registration period, a 1-week 
baseline period, and a 12-week treatment period, similar to previous studies 
[22, 23]. Female outpatients aged 20–64 years were diagnosed according to 
the Rome III criteria. Patients satisfying the inclusion and exclusion criteria were 
monitored during a 1-week baseline period in which data on severity of 
abdominal pain/discomfort and stool consistency were collected to ensure that 
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patients met the criteria. Patients who had not used drugs or undergone 
examinations that could affect the evaluation of study drug efficacy within 10 
days prior to randomization; who recorded all items in the patient diary for ≥5 
days during the baseline period; who had mean severity scores of abdominal 
pain/discomfort of ≥0.7 during the baseline period (a 5-point ordinate scale); in 
whom no type 1 or 2 stool form, as scored by BSFS, was recorded during the 
baseline period; who had bowel movements for ≥5 days during the baseline 
period; and who were not judged ineligible for the study according to the clinical 
laboratory test results received before the baseline period were randomized 
and successively administered treatment. 
 
2) Study Design 
Following the baseline period, eligible patients were randomly assigned 
to 12-week oral treatments with placebo or ramosetron 2.5 μg once daily before 
breakfast. Visits were scheduled at Weeks 2, 4, 8, and 12 (or at discontinuation) 
to assess treatment efficacy, drug compliance, and occurrence of adverse 
events. Randomization was performed in a 1:1 ratio using a block size of 4 with 
a web-based randomization system. All patients, investigators, and sponsors 
were blinded until all observations and evaluations were completed, statistical 
analysis plans were finalized, and all data had been entered. 
 
3) Data Collection 
During the baseline and treatment periods, patients recorded their IBS 
symptoms daily on paper diary cards at bedtime, and electronically entered 
data into a database daily using an interactive voice response system to 
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support the completion of data entry in the paper diary cards. In the diary, 
patients recorded the BSFS types and stool frequencies and scored the 
severity of their abdominal pain/discomfort. Urgency and feeling of incomplete 
evacuation were assessed on a binary scale. Every 7 days during the treatment 
period, patients also graded summarized IBS symptoms compared with the 
baseline period on a 5-point ordinate scale.  
 
4) Efficacy Endpoints 
The co-primary endpoints were monthly responder rate for 
improvement in stool consistency and monthly responder rates for global 
assessment of relief of overall IBS symptoms at last evaluation point. Patients 
with weekly mean BSFS scores of 3 to 5 during a 1-week of the treatment 
period and a decrease of one or more points in mean BSFS scores from the 
baseline period were defined as weekly responders in improvement in stool 
consistency (Table 10). If more than 2 daily scores were missing during any 
week of the study period, the mean score for that week was defined as missing. 
Patients with missing mean BSFS scores were regarded as weekly non 
responders. In global assessment of relief of overall IBS symptoms, patients 
with scores of 0 or 1 at each weekly evaluation point were defined as weekly 
responders (Table 2). Patients who were weekly responders for at least 2 of 
the 4 weeks in a 1- month were considered monthly responders in both primary 
endpoints. The last 4 weeks of the treatment phase constituted the assessment 
period for the primary endpoints. 
Secondary endpoints included monthly responder rates for 
improvement in abnormal bowel habits and relief of abdominal pain/discomfort. 
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Scales measuring IBS symptoms, including severity of abdominal 
pain/discomfort, BSFS, stool frequency, urgency and feeling of incomplete 
evacuation and IBS-QOL were established for the secondary endpoints. All 
adverse events were recorded during the intervention period. 
 
5) Statistical Analysis 
Statistical analysis was performed using SAS Drug Development (ver. 
3.4) and PC-SAS (ver. 9.1.3) (SAS Institute Inc., Cary, NC, USA). Sample sizes 
of 580 patients (290 patients/group) were calculated to provide 90% power to 
detect both a difference in monthly responder rates for global assessment of 
relief of overall IBS symptoms at the last point between the placebo group 
(38%) and the ramosetron 2.5 μg group (53%) and monthly responder rates for 
improvement in stool consistency at the last point between the placebo group 
(21%) and the ramosetron 2.5 μg group (40%) based on the phase II clinical 
study (Clinicaltrials.gov ID: NCT01274000) [24], using the chi-square test with 
a two-sided significance level of 0.05.  
Efficacy analyses included the FAS, which included all patients who 
received at least one dose of the study drug during the treatment period and for 
whom at least one endpoint could be evaluated. Safety analyses were 
performed for all patients who received at least 1 dose of the study drug during 
the treatment period. 
Monthly responder rates for global assessments and improvement in 
stool consistency are expressed as a percentage of responders, and 95% CIs 
are provided. The treatment groups were compared using the chi-square test 
test with a two-sided significance level of 0.05. The superiority of ramosetron 
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2.5 μg to placebo was defined with demonstrating statistically significance to 
placebo in both two co-primary endpoints. BSFS were evaluated using the t-
test. Adverse events were evaluated using Fisher’s exact test. 
 
2.2.3 Results 
1) Improvement in Stool Consistency 
The monthly responder rate for improvement in stool consistency was 
40.8% (95% CI, 35.1-46.6) in the ramosetron 2.5 μg group and 24.3% (95% 
CI,19.4-29.7) in the placebo group (difference, 16.5%; 95% CI,8.9-24.0; 
P<0.001; Figure 21). 
 
2) Global Assessment 
Ramosetron-treated patients showed significantly higher responder 
rates for global assessment of relief of overall IBS symptoms at the last point 
(50.7%; 95% CI, 44.8-56.6) than did placebo-treated patients (32.0%; 95% CI, 
26.7–37.8; difference, 18.6%; 95% CI, 10.7-26.5; P<0.001; Figure 22). Monthly 
responder rates for improvement in abnormal bowel habits were significantly 
higher in the ramosetron 2.5 μg group than in the placebo group (Figure 23A). 
The monthly responder rates for relief of abdominal pain/discomfort in the 
ramosetron 2.5 μg group were also significantly higher than that in the placebo 
group (Figure 23B), except for Month 2.  
 
3) Weekly Changes in Stool Form 
Weekly BSFS scores were significantly lower in the ramosetron 2.5 μg 
group (4.32 ± 1.04) than those in the placebo group (4.80 ± 0.91 at last 
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evaluation point, P < 0.001) throughout treatment period (Figure 24) [25]. 
 
4) Safety 
The incidences of constipation and hard stool considered to be caused 
by the pharmacological action of ramosetron were significantly higher in the 
ramosetron (11.0% and 22.6%, respectively) group than in the placebo group 
(4.6%, P = 0.005; 5.6%, P < 0.001, respectively) (Table 12). However, those 
adverse events observed were mild except that one patient in the ramosetron 
group showed a moderate level of hard stool which recovered immediately. 
Serious adverse events including anemia (one patient) and enterocolitis 
infectious (one patient) occurred only in the placebo group. 
 
2.2.4 Discussion 
This study aimed to verify the hypothesis that that remosetron could 
also be effective in female patients with IBS-D. The newly developed monthly 
responder rate of improvement in stool consistency (Table 10) was used as co-
primary endpoints with monthly responder rates for global assessment of relief 
of overall IBS symptoms (Table 2). Both primary endpoints in the ramosetron 
2.5 μg group showed significantly superior responses to the placebo group at 
all evaluation points. Based on these results, ramosetron was approved for use 
by women. 
Monthly responder rates for improvement in abnormal bowel habits and 
weekly change in stool form showed significant improvement in the ramoseton 
group compared to the placebo group at all evaluation points. On the other 
hand, monthly responder rates for relief of abdominal pain/discomfort and 
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weekly change in the severity of abdominal pain/discomfort showed significant 
improvement at some evaluation points [25]. These results suggested stool 
form is superior to abdominal pain/discomfort to show how ramosetron is 
effective for individual IBS symptoms.  
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Figure 21. Monthly responder rates for improvement in stool consistency 
[Modified Figure 1B in reference 25]. Height: responder rate (%). Error bar: 95% 
CI. P values were calculated using the chi-square test. 
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Figure 22. Monthly responder rates for relief of overall IBS symptoms [Modified 
Figure 1A in reference 25]. Height: responder rate (%). Error bar: 95% CI. P 
values were calculated using the chi-square test. 
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A) 
 
B) 
 
Figure 23. A) Monthly responder rates for improvement in abnormal bowel 
habits [Modified Figure 2B in reference 25]. B) Monthly responder rates for relief 
of abdominal pain/discomfort [Modified Figure 2A in reference 25]. Column 
height: responder rate (%). Error bar: 95% CI. P values were calculated using 
the chi-square test.  
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Figure 24. Weekly changes in BSFS scores. Line graph: mean ± 95% CI. P 
values were calculated using the t-test, as follows. *P < 0.001. 
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Table 12. Incidence of adverse events [25] 
Event 
Placebo 
(n = 284) 
Ramonsetron 2.5 μg 
(n = 292) 
P value 
All adverse events 118 (41.5%) 154 (52.7%) 0.009 
Gastrointestinal disorders 46 (16.2%) 92 (31.5%) < 0.001 
Constipation 13 (4.6%) 32 (11.0%) 0.005 
Hard stool 16 (5.6%) 66 (22.6%) < 0.001 
Infections and infestations 54 (19.0%) 56 (19.2%) 1.000 
Nasopharyngitis 34 (12.0%) 34 (11.6%) 1.000 
Pharyngitis 5 (1.8%) 6 (2.1%) 1.000 
 
Data are expressed as numbers (%). Events with an incidence of ≥ 2% in the ramosetron 
2.5 μg group are listed. P values were calculated using Fisher’s exact test. 
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Chapter 3. Conclusions 
 
The findings and discussion obtained by this research and future 
prospects are summarized below. 
 
Chapter 1 showed the results of the phase IV pilot study to explore and 
examine efficacy variables to assess “clinically meaningful improvements, 
focusing on the patient’s chief complaint and the severity of major IBS 
symptoms” in addition to the global assessment. IBSSI-J showed that most 
patients enrolled had moderate to severe IBS symptoms in the baseline period. 
The highest severity score among each component was for dissatisfaction with 
bowel habits. Second was for interference with QOL and frequency of 
abdominal pain. The patients in this study were considered to have impaired 
QOL. The lowest score of the five components was for intensity of abdominal 
distention, which might be related to a lower contribution of abdominal 
distention in IBS-D. Changes in IBSSI-J score in the ramosetron 5 µg group 
seems to be superior to that of the placebo group numerically at all evaluation 
points, however, differences between ramosetron and placebo were not 
evident. Further investigation will be needed to use this questionnaire as a 
primary endpoint in clinical studies related to the development of 
pharmacological agents for IBS-D patients.  
IBS is characterized by two major IBS symptoms, abdominal 
pain/discomfort and abnormal bowel habits. Regarding the chief complaint that 
patients had before administration, 34.0% of the patients in the ramosetron 5 
µg group and 42.0% of the patients in the placebo group reported abdominal 
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pain/discomfort. Higher proportions of chief complaint in bowel habits were also 
observed in stool form (19.1% in the ramosetron 5 µg group and 18.0% in the 
placebo group) and stool frequency (25.5% in the ramosetron 5 µg group and 
20.0% in the placebo group). When compared to placebo, the greatest 
improvement in symptoms of the chief complaint that patients had before 
administration in the ramosetron 5 µg group was shown in stool consistency. 
Stool consistency correlates with colonic transit time [43, 44] and can be a good 
indicator of bowel function. In rats, ramosetron also clearly reduced stress-
induced diarrhea and accelerated defecation caused by corticotropin-releasing 
hormone [15, 19]. To show how ramosetron is effective for individual IBS 
symptoms, focusing on stool consistency was considered to be acceptable in 
light of the drug’s pharmacological mechanism. If the effect of ramosetron on 
stool consistency is excessive, it leads to constipation. Therefore, it was also 
considered important to define a clinically meaningful “improvement in stool 
consistency”. Patients with weekly mean BSFS scores of 3 to 5 during a 1- 
week of the treatment period and a decrease of one or more points in mean 
BSFS scores from the baseline period were defined as weekly responders. 
Patients who were weekly responders for at least 2 of the 4 weeks in a 1-month 
were defined as monthly responders. 
 
In chapter 2, results of clinical studies were shown, and used the newly 
developed variable, “improvement in stool consistency” as the primary endpoint 
to evaluate the prospective effect of ramosetron. The ramonsetron 5 µg group 
showed significantly higher monthly responder rates in improvement in stool 
consistency compared to the placebo group at all evaluation points in male 
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patients with IBS-D [37]. In the phase III study for female patients with IBS-D, 
improvement in stool consistency was used as co-primary endpoints with global 
assessments and the ramonsetron 2.5 µg group showed superior response to 
the placebo group in both primary endpoints [25]. As a results, ramosetron 2.5 
μg was approved for use by women in May 2015.  
 
Thus, I found “improvement in stool consistency” is the best endpoint 
for clinical studies of ramosetron in patients with IBS-D to clearly show how 
ramosetron is effective for individual IBS symptoms, along with the 
pharmacologic profile of the drug. 
 
Although it was unclear that an improvement of one chief complaint 
influenced the other IBS symptoms of patients, improvement in the chief 
complaint the patient had before administration was more frequent in the 
responder group in global assessment of relief of overall IBS symptoms 
compared to the non-responder group. These relationships were obtained not 
only for stool form, but also for abdominal pain/discomfort and stool frequency. 
In studies with larger patient numbers, ramosetron showed a statistically 
significant improvement in the severity of abdominal pain/discomfort and stool 
frequency compared to placebo at some evaluation points [25, 37]. Ramosetron 
was suggested to improve overall IBS symptoms throughout the improvement 
of individual IBS symptoms like abdominal pain/discomfort, stool form and stool 
frequency, which were assessed as secondary endpoints.  
A greater change in the IBSSI-J overall score and percent change from 
baseline were also observed in the monthly responder group with respect to 
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global assessment of relief of overall IBS symptoms than in the non-responder 
group. This result suggests that global assessment also reflects improvement 
of the symptom severity of patients with IBS-D.  
 
In the phase II study to find the optimal dose of ramosetron (1.25 µg, 
2.5 µg and 5 µg) for female patients with IBS-D [24], the ramosetron 2.5 µg 
group showed a clear improvement in global assessment of relief of overall IBS 
symptoms compared to placebo group. On the other hand, weekly BSFS 
scores were lowest in the ramosetron 5 µg group and the incidence of 
constipation and hard stool increased in a dose-dependent manner. These 
results suggest that patients assessed global assessment of relief of overall 
IBS symptoms negatively, if they felt the effect of ramosetron is excessive. 
Ramosetron 2.5 µg was chosen as the optimal dose of ramosetron for female 
patients to show the most effective and least harmful option. These results are 
consistent with the results of the PK study for ramosetron [45]. Patients can 
assess global assessment of relief of overall IBS symptoms not only in a 
positive direction, but also a negative direction.  
 
Thus, it is considered that global assessment of relief of overall IBS 
symptoms is the best endpoint to show clinically meaningful improvement by 
patients, which includes the assessments of improvement of chief complaint 
and severity of major IBS symptoms.  
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Future Prospects 
 
In recent years, the concept of patient-centricity is increasingly 
emphasized in drug development in Europe and the United States. Patient 
reported outcome (PRO) was developed as a variable to capture evaluation of 
patients. 
The United States Food and Drug Administration (FDA) proposed a 
study design for clinical trials focused on IBS that would assist the 
pharmaceutical industry and investigators who are developing drugs [46]. 
Although they recommend the use of abdominal pain and stool consistency as 
co-primary endpoints for IBS-D, these are provisional endpoints. They require 
the development of multi-item PRO instruments that can capture clinically 
important signs and symptoms of the IBS target population (e.g. IBS-C or IBS-
D). Some PRO measurements are under development in the study of IBS [41, 
47] in accordance with the FDA guidance for PRO [48]. In its PRO guidance, 
the FDA recommends that acceptable PRO must be couched in an explicit and 
evidence based conceptual framework. In the future, PRO measurements that 
include validated assessment of multiple chief complaints might be available in 
clinical trials related to IBS. 
The Japanese Society of Gastroenterology developed evidence-based 
clinical practice guidelines for IBS [49]. They recommend treating IBS patients, 
as they can feel improvement in IBS symptoms, based on the assessment of 
patient-reported outcomes. Global assessment of relief of overall IBS 
symptoms in this study can be a very useful efficacy variable in IBS-D to meet 
with their recommendation. “Improvement in stool consistency” is calculated by 
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the stool form, which is also evaluated by patients using the objective standard 
BSFS. It showed the normalization of stool form and how ramoserton was 
effective for individual IBS symptoms. Figure 25 summarizes the efficacy 
variables in a clinical study of ramosetron for IBS-D. Using “improvement in 
stool consistency” in addition to global assessment is important to add scientific 
value to subjective evaluation by patients. 
 
IBS is not a life-threatening disease, but has been shown to limit the 
activity of patients and to negatively impact social functioning, with substantial 
economic loss. QOL is impaired. Ramosetron (5 µg for male and 2.5 µg for 
female) significantly improved overall scores, dysphoria, interference with 
activity, and food avoidance included in IBS-QOL, disease specific health-
related QOL compared to placebo [25, 37].  
Development of new medicines using the evidence of PRO can 
increase treatment options for doctors and patients with IBS-D. As a result, it 
might improve medical economics. PRO is not yet very popular in Japan. This 
research is expected to contribute to the development of variables in clinical 
studies for other diseases, as patient-centricity becomes increasingly important.  
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Figure 25. Summary of efficacy variables in clinical study of IBS-D. 
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